Drugmakers in China take aim at pharma’s lucrative cancer fighters

Checkpoint inhibitors have become blockbuster drugs in recent years, but now face new rivals developed in China.


A coming wave of Chinese cancer drugs could provide patients with cheaper alternatives to some celebrated and costly therapies, but gaining traction will mean going up against some of the global pharmaceutical industry’s most lucrative and well-protected franchises.

Treatments known as checkpoint inhibitors that free the immune system to attack tumors have become blockbusters in recent years – Merck & Co.’s Keytruda and Bristol-Myers Squibb Co.’s Opdivo are cornerstones of a USD 150bn global market.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs